MCID: PRT030
MIFTS: 49

Parathyroid Gland Disease

Categories: Endocrine diseases

Aliases & Classifications for Parathyroid Gland Disease

MalaCards integrated aliases for Parathyroid Gland Disease:

Name: Parathyroid Gland Disease 12 15
Parathyroid Diseases 44 73
Abnormality of the Parathyroid Gland 29
Disease of Parathyroid Glands 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11201
ICD10 33 E21.5 E21.4
ICD9CM 35 252 252.9
MeSH 44 D010279
NCIt 50 C26844
UMLS 73 C0030517

Summaries for Parathyroid Gland Disease

Disease Ontology : 12 An endocrine system disease that is located in the parathyroid gland.

MalaCards based summary : Parathyroid Gland Disease, also known as parathyroid diseases, is related to hypoparathyroidism and hyperparathyroidism. An important gene associated with Parathyroid Gland Disease is PTH (Parathyroid Hormone), and among its related pathways/superpathways are Signaling by GPCR and G alpha (s) signalling events. The drugs Betamethasone and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include the parathyroid gl, kidney and bone, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 76 Many conditions are associated with disorders of the function of the parathyroid gland. Parathyroid... more...

Related Diseases for Parathyroid Gland Disease

Diseases related to Parathyroid Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Related Disease Score Top Affiliating Genes
1 hypoparathyroidism 29.3 AIRE BGLAP CASR FGF23 GCM2 PTH
2 hyperparathyroidism 27.9 BGLAP CALCA CASR CDC73 FGF23 GCM2
3 primary hyperparathyroidism 25.5 BGLAP CALCA CASR CDC73 FGF23 GCM2
4 parathyroid transitional clear cell adenoma 10.8 MEN1 PTH
5 sclerosing hepatic carcinoma 10.7 PTH PTHLH
6 hyperparathyroidism 1 10.7 CDC73 MEN1
7 fibrogenesis imperfecta ossium 10.7 CALCA PTH
8 invasive malignant thymoma 10.7 PTH PTHLH
9 axial osteomalacia 10.7 BGLAP PTH
10 hypocalciuric hypercalcemia, familial, type ii 10.6 CASR PTH
11 pancreatic somatostatinoma 10.6 CALCA MEN1
12 familial hypocalciuric hypercalcemia 10.6 CASR CDC73 PTH
13 multiple endocrine neoplasia, type iv 10.6 MEN1 RET
14 paraneoplastic syndromes 10.6 FGF23 PTHLH
15 hypocalciuric hypercalcemia, familial, type iii 10.6 CASR PTH PTHLH
16 endocrine organ benign neoplasm 10.5 CDC73 MEN1 PTH
17 clear cell adenoma 10.5 MEN1 PTH PTHLH
18 organ system benign neoplasm 10.5 CDC73 MEN1 PTH
19 hypoadrenalism 10.5 CALCA PTHLH
20 jaw cancer 10.5 PTH PTHLH
21 chief cell adenoma 10.5 GCM2 PTH
22 pancreatic cholera 10.5 CALCA MEN1
23 cloacogenic carcinoma 10.4 CALCA PTH PTHLH
24 oncogenic osteomalacia 10.4 FGF23 PTH PTHLH
25 multiple endocrine neoplasia, type iib 10.4 CALCA MEN1 RET
26 water-clear cell adenoma 10.4 PPP1R3C PTH
27 extraskeletal chondroma 10.4 BGLAP PTH PTHLH
28 osteoporosis, juvenile 10.4 BGLAP CALCA
29 pulmonary alveolar microlithiasis 10.4 FGF23 PTH
30 islet cell tumor 10.4 CALCA MEN1 PTHLH
31 pseudohypoparathyroidism, type ib 10.4 BGLAP PTH PTHLH
32 multiple endocrine neoplasia 10.4 CALCA MEN1 RET
33 hypophosphatasia, adult 10.4 BGLAP CALCA PTH
34 nontoxic goiter 10.4 BGLAP CALCA
35 endocrine gland cancer 10.3 CALCA MEN1 RET
36 glucocorticoid-induced osteoporosis 10.3 BGLAP CALCA PTH
37 uremia 10.3 CASR PTH VDR
38 impaired renal function disease 10.3 BGLAP FGF23 PTH
39 hypervitaminosis d 10.3 FGF23 PTH VDR
40 thyroid carcinoma, familial medullary 10.3 CALCA MEN1 RET
41 paget's disease of bone 10.3 BGLAP CALCA PTH
42 hypophosphatemic rickets, x-linked dominant 10.3 FGF23 PTH VDR
43 hypophosphatemia 10.3 BGLAP FGF23 PTH
44 hyperparathyroidism 2 with jaw tumors 10.3 CASR CDC73 MEN1 RET
45 hyperparathyroidism 3 10.3 CDC73 GCM2 MEN1
46 cell type benign neoplasm 10.3 CDC73 MEN1 PTH RET
47 carcinoid syndrome 10.2 CALCA MEN1
48 thyroid cancer, nonmedullary, 2 10.2 CALCA MEN1 RET
49 fibrous dysplasia 10.2 BGLAP CALCA FGF23
50 autoimmune polyendocrine syndrome type 1 10.2 AIRE CASR

Graphical network of the top 20 diseases related to Parathyroid Gland Disease:



Diseases related to Parathyroid Gland Disease

Symptoms & Phenotypes for Parathyroid Gland Disease

MGI Mouse Phenotypes related to Parathyroid Gland Disease:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 CDC73 ADCY10 CASR MEN1 PTHLH PPP1R3C
2 homeostasis/metabolism MP:0005376 10.23 CDC73 GCM2 ADCY10 AIRE FGF23 CASR
3 cardiovascular system MP:0005385 10.2 CDC73 ADCY10 FGF23 MEN1 PTHLH PPP1R3C
4 endocrine/exocrine gland MP:0005379 10.19 CDC73 GCM2 AIRE FGF23 CASR RET
5 growth/size/body region MP:0005378 10.18 CASR FGF3 CDC73 AIRE FGF23 MEN1
6 mortality/aging MP:0010768 10.15 CDC73 AIRE FGF23 CASR FGF3 PPP1R3C
7 immune system MP:0005387 10.13 FGF3 CDC73 AIRE FGF23 CASR PTHLH
8 digestive/alimentary MP:0005381 10.11 CDC73 AIRE FGF23 CASR RET PTHLH
9 craniofacial MP:0005382 10 CDC73 MEN1 PTHLH GCM2 PTH VDR
10 nervous system MP:0003631 9.91 FGF3 CDC73 AIRE MEN1 PTHLH PPP1R3C
11 limbs/digits/tail MP:0005371 9.88 FGF3 FGF23 PTHLH PTH VDR RET
12 muscle MP:0005369 9.8 CASR CDC73 MEN1 PPP1R3C VDR RET
13 renal/urinary system MP:0005367 9.7 CDC73 FGF23 CASR PTHLH RET GCM2
14 reproductive system MP:0005389 9.61 FGF3 CDC73 ADCY10 AIRE FGF23 MEN1
15 skeleton MP:0005390 9.23 FGF3 CDC73 FGF23 CASR PTHLH PTH

Drugs & Therapeutics for Parathyroid Gland Disease

Drugs for Parathyroid Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
2
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
3
Calcium acetate Approved, Investigational Phase 4,Phase 3,Not Applicable 62-54-4
4
Sevelamer Approved Phase 4,Phase 3,Phase 2,Not Applicable 52757-95-6
5
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
6
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1 615258-40-7
7
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
8
Alendronate Approved Phase 4,Not Applicable 121268-17-5, 66376-36-1 2088
9
Zoledronic acid Approved Phase 4,Phase 1 118072-93-8 68740
10
Pamidronate Approved Phase 4 40391-99-9 4674
11
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 471-34-1
12
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
13
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
14
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
15
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
16 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1406-16-2
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
19
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 67-97-0 6221 5280795
20
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 32222-06-3 134070 5280453
21
Alfacalcidol Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 41294-56-8 5282181
22
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
23 Anti-Asthmatic Agents Phase 4
24 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2,Not Applicable
25 Betamethasone acetate Phase 4
26 Betamethasone benzoate Phase 4
27 Betamethasone sodium phosphate Phase 4
28 Betamethasone Valerate Phase 4 2152-44-5
29 Betamethasone-17,21-dipropionate Phase 4
30 glucocorticoids Phase 4,Phase 1,Phase 2,Not Applicable
31 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Respiratory System Agents Phase 4
35 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Calcimimetic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Cinacalcet Hydrochloride Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Retinol palmitate Phase 4
44 Calcifediol Phase 4,Phase 3,Phase 1,Not Applicable 19356-17-3
45 Hydroxycholecalciferols Phase 4,Phase 3,Phase 2,Not Applicable
46 Antimetabolites Phase 4,Phase 2,Not Applicable
47 Hypolipidemic Agents Phase 4,Phase 2,Not Applicable
48 Lipid Regulating Agents Phase 4,Phase 2,Not Applicable
49 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
50 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 357)
# Name Status NCT ID Phase Drugs
1 Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
2 Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
3 Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
4 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Unknown status NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
5 Effect of Epidural Steroid Injection on Bone Mineral Density in Postmenopausal Women Completed NCT00941473 Phase 4 Triamcinilone (kenalog)
6 The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid Completed NCT02056730 Phase 4 calcium sensing receptor agonist
7 Denosumab in Primary Hyperparathyroidism Completed NCT01558115 Phase 4 Denosumab
8 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
9 A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis Completed NCT00454350 Phase 4 Hectorol (doxercalciferol injection);Zemplar (Paricalcitol injection)
10 A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis Completed NCT00418600 Phase 4 Hectorol® (doxercalciferol capsules);doxercalciferol capsules, Hectorol®;doxercalciferol capsules, Hectorol® capsules
11 Treatment Adhesion in Dialysis Patients Treated With Cinacalcet Completed NCT01573520 Phase 4
12 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4 Paricalcitol;Darbepoetin alfa
13 Trial to Optimize Mineral Outcomes in Dialysis Patients Completed NCT01100723 Phase 4
14 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease Completed NCT00257920 Phase 4 Zemplar® injection;Hectorol® injection
15 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4 Zemplar;Calcijex
16 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
17 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Completed NCT00528788 Phase 4 doxercalciferol
18 Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate Completed NCT01222026 Phase 4 Strontium Ranelate + Ca/Vitamin-D;Placebo
19 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
20 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4 Cinacalcet
21 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4 cinacalcet;control
22 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
23 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4 Hectorol (doxercalciferol capsules);Zemplar (paricalcitol injection)
24 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
25 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Completed NCT00135304 Phase 4 Sensipar®;Vitamin D
26 A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer Completed NCT00037518 Phase 4 AMG 073
27 Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
28 Vitamin D Repletion in Primary Hyperparathyroidism Completed NCT01306656 Phase 4 10,000 IU Vitamin D3
29 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Completed NCT00431496 Phase 4 Cinacalcet
30 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4 Hectorol (doxercalciferol capsules), 0.5mcg
31 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4 paricalcitol injection
32 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
33 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet
34 Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation Completed NCT01675089 Phase 4 Zoledronic acid
35 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4 25 OH vitamin D
36 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
37 Evaluation of a Cincalcet Suppression Test Completed NCT01103206 Phase 4 cinacalcet;cinacalcet dose 1;cinacalcet dose 2
38 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed NCT00977080 Phase 4 Paricalcitol;Cinacalcet
39 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
40 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
41 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
42 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
43 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Completed NCT00958451 Phase 4 Paricalcitol;Ergocalciferol
44 Does Treatment of Hypovitaminosis D Increase Calcium Absorption? Completed NCT00581828 Phase 4 Vitamin D
45 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4 Sensipar
46 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
47 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
48 Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT Recruiting NCT03123406 Phase 4 Cinacalcet HCl
49 Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients Recruiting NCT03182699 Phase 4
50 Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Recruiting NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet

Search NIH Clinical Center for Parathyroid Gland Disease

Cochrane evidence based reviews: parathyroid diseases

Genetic Tests for Parathyroid Gland Disease

Genetic tests related to Parathyroid Gland Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Parathyroid Gland 29

Anatomical Context for Parathyroid Gland Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Parathyroid Gland Disease:

19
The Parathyroid Gl

MalaCards organs/tissues related to Parathyroid Gland Disease:

41
Kidney, Bone, Thyroid, Thymus, Testes, Heart, Endothelial

Publications for Parathyroid Gland Disease

Articles related to Parathyroid Gland Disease:

# Title Authors Year
1
Sporadic multiple parathyroid gland disease-a consensus report of the European Society of Endocrine Surgeons (ESES). ( 26542689 )
2015
2
[Molecular aspects of the etiopathogenesis of the parathyroid gland diseases]. ( 16350727 )
2005
3
Mortality in sporadic primary hyperparathyroidism: nationwide cohort study of multiple parathyroid gland disease. ( 15523390 )
2004
4
In situ correlation of synthesis and storage of parathormone in parathyroid gland disease. ( 8433215 )
1993
5
Parathyroid gland disease and hypercalcemia. ( 2223448 )
1990
6
Nuclear medicine in diagnosis and treatment of diseases of the head and neck. I. Salivary and parathyroid gland disease and one identification and staging of head and neck tumors. ( 6273364 )
1981

Variations for Parathyroid Gland Disease

Copy number variations for Parathyroid Gland Disease from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 160275 22 11800000 24300000 Microdeletion parathyroid gland dysfunction

Expression for Parathyroid Gland Disease

Search GEO for disease gene expression data for Parathyroid Gland Disease.

Pathways for Parathyroid Gland Disease

GO Terms for Parathyroid Gland Disease

Cellular components related to Parathyroid Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.26 ADCY10 CALCA CASR RET
2 axon GO:0030424 8.92 ADCY10 CALCA CASR RET

Biological processes related to Parathyroid Gland Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.99 AIRE CDC73 GCM2 MEN1 PTH VDR
2 negative regulation of cell proliferation GO:0008285 9.91 CDC73 MEN1 PTHLH VDR
3 cell-cell signaling GO:0007267 9.83 CALCA FGF3 PTH PTHLH
4 MAPK cascade GO:0000165 9.8 FGF23 FGF3 MEN1 RET
5 regulation of signaling receptor activity GO:0010469 9.8 CALCA FGF23 FGF3 PTH PTHLH
6 peptidyl-tyrosine phosphorylation GO:0018108 9.79 FGF23 FGF3 RET
7 skeletal system development GO:0001501 9.67 BGLAP PTH PTHLH VDR
8 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.63 CALCA PTH PTHLH
9 decidualization GO:0046697 9.61 MEN1 VDR
10 regulation of bone mineralization GO:0030500 9.6 BGLAP FGF23
11 vasodilation GO:0042311 9.59 CALCA CASR
12 response to pain GO:0048265 9.58 CALCA RET
13 response to vitamin D GO:0033280 9.58 BGLAP PTH
14 negative regulation of chondrocyte differentiation GO:0032331 9.57 PTH PTHLH
15 positive regulation of ossification GO:0045778 9.56 CALCA PTH
16 obsolete positive regulation of cAMP biosynthetic process GO:0030819 9.55 PTH PTHLH
17 vitamin D metabolic process GO:0042359 9.54 FGF23 VDR
18 cellular phosphate ion homeostasis GO:0030643 9.48 FGF23 GCM2
19 response to fibroblast growth factor GO:0071774 9.43 CASR PTH
20 osteoblast development GO:0002076 9.33 BGLAP MEN1 PTHLH
21 cAMP metabolic process GO:0046058 9.32 PTH PTHLH
22 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.26 FGF23 VDR
23 cellular response to vitamin D GO:0071305 9.13 BGLAP CASR FGF23
24 cellular calcium ion homeostasis GO:0006874 9.02 CALCA CASR GCM2 PTH VDR

Molecular functions related to Parathyroid Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.5 FGF23 FGF3 RET
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 FGF23 FGF3 RET
3 fibroblast growth factor receptor binding GO:0005104 9.26 FGF23 FGF3
4 hormone activity GO:0005179 9.13 CALCA PTH PTHLH
5 peptide hormone receptor binding GO:0051428 8.62 PTH PTHLH

Sources for Parathyroid Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....